BRIEF-Bioage Labs Inc - Announces Positive Interim Phase 1 Data For BGE-102

Reuters12-04

Dec 4 (Reuters) - BIOAGE Labs Inc BIOA.O:

BIOAGE LABS INC - ANNOUNCES POSITIVE INTERIM PHASE 1 DATA FOR BGE-102, A NOVEL BRAIN-PENETRANT NLRP3 INHIBITOR
BIOAGE LABS INC - BGE-102 WELL-TOLERATED IN SAD AND INITIAL MAD COHORTS, WITH A PHARMACOKINETIC PROFILE SUPPORTING ONCE-DAILY ORAL DOSING

Source text: ID:nGNX4blr0y

Further company coverage: BIOA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588887015?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-04 22:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588887015","market":"nz","top_or_hot":-1,"title":"BRIEF-Bioage Labs Inc - Announces Positive Interim Phase 1 Data For BGE-102","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Bioage Labs Inc - Announces Positive Interim Phase 1 Data For BGE-102</title></head><body><p><span>Dec 4 (Reuters)</span><span> - </span>BIOAGE Labs Inc <span>BIOA.O</span>:</p><ul><li><p>BIOAGE LABS INC - ANNOUNCES POSITIVE INTERIM PHASE 1 DATA FOR BGE-102, A NOVEL BRAIN-PENETRANT NLRP3 INHIBITOR</p></li><li><p>BIOAGE LABS INC - BGE-102 WELL-TOLERATED IN SAD AND INITIAL MAD COHORTS, WITH A PHARMACOKINETIC PROFILE SUPPORTING ONCE-DAILY ORAL DOSING</p></li></ul><p>Source text: <span>ID:nGNX4blr0y</span></p><p>Further company coverage: <span>BIOA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Bioage Labs Inc - Announces Positive Interim Phase 1 Data For BGE-102</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Bioage Labs Inc - Announces Positive Interim Phase 1 Data For BGE-102\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-04 22:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Bioage Labs Inc - Announces Positive Interim Phase 1 Data For BGE-102</title></head><body><p><span>Dec 4 (Reuters)</span><span> - </span>BIOAGE Labs Inc <span>BIOA.O</span>:</p><ul><li><p>BIOAGE LABS INC - ANNOUNCES POSITIVE INTERIM PHASE 1 DATA FOR BGE-102, A NOVEL BRAIN-PENETRANT NLRP3 INHIBITOR</p></li><li><p>BIOAGE LABS INC - BGE-102 WELL-TOLERATED IN SAD AND INITIAL MAD COHORTS, WITH A PHARMACOKINETIC PROFILE SUPPORTING ONCE-DAILY ORAL DOSING</p></li></ul><p>Source text: <span>ID:nGNX4blr0y</span></p><p>Further company coverage: <span>BIOA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA0DA:1","article_id":"2588887015","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588887015","pubTimestamp":1764857391,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Bioage Labs Inc - Announces Positive Interim Phase 1 Data For BGE-102Dec 4 (Reuters) - BIOAGE Labs Inc BIOA.O:BIOAGE LABS INC - ANNOUNCES POSITIVE INTERIM PHASE 1 DATA FOR BGE-102, A NOVEL BRAIN","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BIOA":"BioAge Labs Inc."},"translate_title":"简介-Bioage Labs Inc-宣布BGE-102的积极中期1期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIOA":0.9},"content_text":"BRIEF-Bioage Labs Inc - Announces Positive Interim Phase 1 Data For BGE-102Dec 4 (Reuters) - BIOAGE Labs Inc BIOA.O:BIOAGE LABS INC - ANNOUNCES POSITIVE INTERIM PHASE 1 DATA FOR BGE-102, A NOVEL BRAIN-PENETRANT NLRP3 INHIBITORBIOAGE LABS INC - BGE-102 WELL-TOLERATED IN SAD AND INITIAL MAD COHORTS, WITH A PHARMACOKINETIC PROFILE SUPPORTING ONCE-DAILY ORAL DOSINGSource text: ID:nGNX4blr0yFurther company coverage: BIOA.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588887015","isCrawlerRequest":true}